{"id":46117,"date":"2026-07-28T03:34:00","date_gmt":"2026-07-28T01:34:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=904a8db7763b897b187ebf527d5b1657"},"modified":"2026-07-28T03:34:00","modified_gmt":"2026-07-28T01:34:00","slug":"securities-fraud-investigation-into-capricor-therapeutics-inc-capr-announced-following-critical-fda-review-ahead-of-advisory-committee-meeting-shareholders-who-lost-money-urged-to-contac","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=46117","title":{"rendered":"Securities Fraud Investigation Into Capricor Therapeutics, Inc. (CAPR) Announced Following Critical FDA Review Ahead of Advisory Committee Meeting \u2013 Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz<\/a> announces an investigation of Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR<\/a>) on behalf of investors concerning the Company\u2019s possible violations of federal securities laws.<\/p><\/a><\/a>

\nIF YOU ARE AN INVESTOR WHO LOST MONEY ON CAPRICOR THERAPEUTICS, INC. (CAPR), CLICK <\/b>HERE<\/b><\/a> TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.<\/b><\/p>

\nWhat Is The Investigation About?<\/b><\/p>

\nOn July 27, 2026, the US Food and Drug Administration released briefing documents ahead of its advisory committee meeting with Capricor regarding the Company's cell therapy for a heart condition related to Duchenne muscular dystrophy.<\/p>

\nAmong other things, the briefing documents take issue with the manner in which Capricor measured results after the therapy's late-stage trial ended, stating the \"FDA does not consider the conversion of raw change to percent change and then back to raw change to have been scientifically justified<\/b><\/i>, as it adds complexity and reduces accuracy.\" The briefing documents conclude that, among other things, \"the benefit-risk assessment for deramiocel appears unfavorable in the absence of evidence of effectiveness.\"<\/b><\/i><\/p>

\nCantor Fitzgerald analyst Kristen Kluska published an investor note on the issue, stating the FDA\u2019s \u201cbriefing documents paint an ugly picture\u201d<\/b><\/i> and \u201craise several concerns and make allegations about the integrity of data collecting<\/b><\/i>.\u201d<\/p>

\nOn this news, shares of Capricor stock declined as much as $12.29, or 62.39%, during intraday trading on July 27, 2026.<\/p>

\nContact Us To Participate or Learn More:<\/b><\/p>

\nIf you purchased Capricor securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:<\/p>

\nThe Law Offices of Frank R. Cruz,\n2121 Avenue of the Stars, Suite 800,\nCentury City, California 90067\nCall us at: 310-914-5007\nEmail us at: info@frankcruzlaw.com<\/a>Visit our website at: www.frankcruzlaw.com<\/a>.\nFollow us for updates on Twitter at twitter.com\/FRC_LAW<\/a>.<\/p>

\nIf you inquire by email, please include your mailing address, telephone number, and number of shares purchased.<\/p>

\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

\nThe Law Offices of Frank R. Cruz, Los Angeles\nFrank R. Cruz\n310-914-5007\nfcruz@frankcruzlaw.com<\/a>www.frankcruzlaw.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of Capricor Therapeutics, Inc. (\u201cCapricor\u201d or the \u201cCompany\u201d) (NASDAQ: CAPR) on behalf of investors concerning the Company\u2019s possible violations of federal securit…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-46117","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46117"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46117\/revisions"}],"predecessor-version":[{"id":46118,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/46117\/revisions\/46118"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}